Amcor plc (AMCR) Stock Analysis and Metrics

Amcor

NYSE: AMCR

$43.94 ▼ -0.90 (-2.01%)

At close: Jul 17, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap1.00 Bn

P/E1.60

P/S0.05

Div. Yield1.18

ROIC (Qtr)0.00

Total Debt (Qtr)15.29 Bn

Revenue Growth (1y) (Qtr)77.44

Add ratio to table…

About

Amcor plc is a public limited company incorporated under the Laws of the Bailiwick of Jersey. The company develops and produces responsible consumer packaging and dispensing solutions for nutrition health beauty and wellness categories. Its product portfolio includes flexible packaging rigid packaging cartons and closures made from a variety of materials such as paper aluminum polymer resins recycled and bio based substrates. Amcor plc serves customers worldwide by delivering packaging that is more sustainable functional and appealing. The firm leverages more than 150 years of heritage originating in Australia and the United States to drive innovation and sustainability across its global operations.

Amcor plc generates revenue primarily from the sale of its packaging products to manufacturers in the food beverage personal care and healthcare sectors. The company offers flexible packaging rigid packaging cartons and dispensing closures that are tailored to meet specific performance sustainability and cost requirements of its customers. In fiscal year 2025 the Global Flexible Packaging Solutions segment contributed approximately seventy two percent of consolidated net sales while the Global Rigid Packaging Solutions segment contributed about twenty eight percent. Revenue is driven by volume growth price adjustments and the introduction of new sustainable material solutions. The firm also earns income from licensing its intellectual property and providing technical support services to clients.

The company operates through the following segments: Global Flexible Packaging Solutions and Global Rigid Packaging Solutions. These segments are defined based on the nature of the products they produce and the markets they serve rather than on geographic boundaries. Each segment encompasses a distinct set of manufacturing facilities technology platforms and customer relationships. The segment reporting framework follows the requirements of Accounting Standards Codification 280.

• Global Flexible Packaging Solutions develops and supplies flexible packaging globally using polymer resin aluminum and fiber based materials. As of June 30 2025 the segment employed approximately forty two thousand employees across two hundred ten manufacturing and support facilities in thirty six countries. In fiscal year 2025 this segment accounted for approximately seventy two percent of consolidated net sales. The segment focuses on creating lightweight high barrier packaging solutions for food beverage personal care and healthcare applications.

• Global Rigid Packaging Solutions manufactures rigid packaging containers closures dispensing and pharma devices and related products worldwide. As of June 30 2025 the segment employed approximately thirty four thousand employees at two hundred thirteen manufacturing and support facilities in thirty four countries. In fiscal year 2025 the segment accounted for approximately twenty eight percent of consolidated net sales. The segment emphasizes durability safety and regulatory compliance for products serving nutrition health beauty and wellness markets.

Amcor plc holds a leading position as a global supplier of consumer packaging solutions competing in highly fragmented markets that include flexible rigid carton and closure products. The company differentiates itself through its extensive global scale broad material expertise strong research and development capabilities and a deep sustainability agenda supported by over seven thousand patents and a network of innovation centers. Competitors include 3M AptarGroup Inc Ball Corporation CCL Industries Inc Crown Holdings Inc Graphic Packaging Holding Company Huhtamaki Oyj International Paper Company Mayr Melmhof Karton AG O I Glass Inc Sealed Air Corporation Sigma Plastics Group Silgan Holdings Inc Sonoco Products Company and numerous private firms. Amcor plc s competitive advantages stem from its ability to deliver innovative sustainable packaging at scale while maintaining cost efficiency and technical performance.

Amcor plc serves a diverse customer base consisting of manufacturers in the food beverage personal care and healthcare industries. Its customers range from multinational corporations to regional producers who require packaging for products such as dairy snacks beverages cosmetics pharmaceuticals and household goods. The company reports that no single customer accounted for more than ten percent of consolidated net sales in the last three fiscal years indicating a balanced reliance across many accounts. Amcor plc works closely with these customers to develop customized packaging solutions that meet performance sustainability and regulatory requirements.

Investment Thesis

▲ Bull case

Amcor is strategically positioned to capture significant growth from its accelerated synergy realization, which is exceeding initial targets and creating a powerful foundation for sustained earnings expansion. Management highlighted that synergy delivery reached $77 million in Q3 FY26 and $170 million for the first nine months, putting them on track to deliver $270 million in synergies for the full fiscal year—well above the initial $260 million Year 1 target. This acceleration is being driven by strong execution in G&A and procurement synergies, which are ramping up as planned with clear line of sight to $160 million in Year 1 and $325 million by FY28. More importantly, growth synergies are now exceeding $110 million in annualized revenue, well on track toward the $280 million 3-year target, with early wins already contributing a few million dollars to Q3 earnings and expected to ramp up further in H2 CY26. These growth synergies stem from the combined Amcor-Berry portfolio’s ability to sell integrated systems rather than components, leveraging complementary technology footprints and additional capacity—exemplified by recent wins like the global pharma contract for oral dose GLP-1 drug packaging across Europe and North America. The company’s focus on six high-margin, innovation-led categories (healthcare, beauty and wellness, proteins, liquids, foodservice, and pet care) continues to outperform the broader portfolio, with focus category volumes flat while the overall company was down 1.5%, reflecting favorable mix and leadership in durable end markets. As Amcor simplifies its business by exiting noncore assets and reinvesting in these focus areas, the overall growth profile, quality, and resilience of the enterprise are set to improve meaningfully. Furthermore, the planned transition to a December 31 fiscal year-end effective in 2027 will enhance comparability with peers and simplify investor modeling, while the migration of select corporate functions to a new U.S. headquarters in Miami will align resources more closely with Amcor’s operating footprint—particularly in its key North American and Latin American markets—potentially unlocking operational efficiencies and faster decision-making. These structural changes, combined with a proven ability to navigate supply chain volatility and inflation through collaborative pricing mechanisms with customers, suggest the market is underestimating the durability of Amcor’s earnings power and the long-term value creation from its post-merger integration. With adjusted EPS guidance for FY26 implying more than 20% year-over-year growth in Q4 and a clear path to deleveraging toward a 2.5–3x leverage range by FY27, Amcor’s underlying earnings momentum is stronger than current expectations suggest.

Amcor is strategically positioned to capture significant growth from its accelerated synergy realization, which is exceeding initial targets and creating a powerful foundation for sustained earnings expansion. Management highlighted that synergy delivery reached $77 million in Q3 FY26 and $170 million for the first nine months, putting them on track to deliver $270 million in synergies for the full fiscal year—well above the initial $260 million Year 1 target. This acceleration is being driven by strong execution in G&A and procurement synergies, which are ramping up as planned with clear line of sight to $160 million in Year 1 and $325 million by FY28. More importantly, growth synergies are now exceeding $110 million in annualized revenue, well on track toward the $280 million 3-year target, with early wins already contributing a few million dollars to Q3 earnings and expected to ramp up further in H2 CY26. These growth synergies stem from the combined Amcor-Berry portfolio’s ability to sell integrated systems rather than components, leveraging complementary technology footprints and additional capacity—exemplified by recent wins like the global pharma contract for oral dose GLP-1 drug packaging across Europe and North America. The company’s focus on six high-margin, innovation-led categories (healthcare, beauty and wellness, proteins, liquids, foodservice, and pet care) continues to outperform the broader portfolio, with focus category volumes flat while the overall company was down 1.5%, reflecting favorable mix and leadership in durable end markets. As Amcor simplifies its business by exiting noncore assets and reinvesting in these focus areas, the overall growth profile, quality, and resilience of the enterprise are set to improve meaningfully. Furthermore, the planned transition to a December 31 fiscal year-end effective in 2027 will enhance comparability with peers and simplify investor modeling, while the migration of select corporate functions to a new U.S. headquarters in Miami will align resources more closely with Amcor’s operating footprint—particularly in its key North American and Latin American markets—potentially unlocking operational efficiencies and faster decision-making. These structural changes, combined with a proven ability to navigate supply chain volatility and inflation through collaborative pricing mechanisms with customers, suggest the market is underestimating the durability of Amcor’s earnings power and the long-term value creation from its post-merger integration. With adjusted EPS guidance for FY26 implying more than 20% year-over-year growth in Q4 and a clear path to deleveraging toward a 2.5–3x leverage range by FY27, Amcor’s underlying earnings momentum is stronger than current expectations suggest.

▼ Bear case

Amcor faces significant near-term headwinds that the market may be underappreciating, particularly surrounding the sustainability of its inventory-driven free cash flow protection and the longevity of its pricing power amid persistent inflationary pressures. While management asserts that holding elevated inventory levels is a temporary measure to ensure supply continuity during Middle East-related resin volatility, the CFO explicitly acknowledged that this decision has already reduced fiscal 2026 free cash flow guidance from $1.8–1.9 billion to $1.5–1.6 billion—a $300 million drag directly tied to carrying inventory at higher costs. More concerning is the admission that beyond Q4, the cash flow implications remain "unpredictable" and contingent on supply chain normalization, with no assurance that the inventory build will be unwound without further earnings pressure. This working capital strain comes at a time when adjusted leverage is already projected to finish FY26 at 3.4–3.5x—modestly above the original guidance and driven by both lower-than-expected EBITDA (due to 2% volume declines vs. guidance assumptions) and the inventory impact—pushing the company further from its long-term target of 2.5–3x leverage. Although Amcor remains committed to deleveraging, the path back to target relies on uncertain assumptions about continued synergy capture and divestiture proceeds, both of which face execution risks. The company has made progress on noncore divestitures, closing six deals worth ~$500 million in transaction value, yet it admittedly remains in early stages on share gain efforts and has not demonstrated an ability to meaningfully offset volume declines through market share gains despite its global scale. Volume performance continues to lag, with overall volumes down 1.5% in Q3 FY26—equally split between core and noncore businesses—and only emerging markets showing mid-single-digit growth, while North America and Europe remain weak due to winter storm impacts and softer demand. Even the focus categories, while outperforming the total company, were merely flat, signaling a lack of underlying organic growth momentum. Furthermore, while management highlights collaborative pricing discussions with customers to pass through inflation, they conceded that 30% of the business lacks contracted pricing and relies on general price increases, leaving a meaningful portion exposed to margin pressure if consumer resistance limits their ability to pass along costs. The healthcare segment—a stated focus area—remained a particular point of weakness, with volumes slightly down despite positives like new facility openings and pharma wins, suggesting that even in preferred end markets, demand is fragile. Finally, the upcoming fiscal year-end change to December 31, while intended to improve comparability, introduces a six-month stub period (July–December 2026) that could complicate year-over-year comparisons and obscure trends during a potentially volatile macroeconomic period. These factors collectively suggest the market may be ignoring the durability of Amcor’s earnings recovery and the risk that current cost-mitigation tactics are merely delaying, not solving, structural challenges in demand and pricing power.

Amcor faces significant near-term headwinds that the market may be underappreciating, particularly surrounding the sustainability of its inventory-driven free cash flow protection and the longevity of its pricing power amid persistent inflationary pressures. While management asserts that holding elevated inventory levels is a temporary measure to ensure supply continuity during Middle East-related resin volatility, the CFO explicitly acknowledged that this decision has already reduced fiscal 2026 free cash flow guidance from $1.8–1.9 billion to $1.5–1.6 billion—a $300 million drag directly tied to carrying inventory at higher costs. More concerning is the admission that beyond Q4, the cash flow implications remain "unpredictable" and contingent on supply chain normalization, with no assurance that the inventory build will be unwound without further earnings pressure. This working capital strain comes at a time when adjusted leverage is already projected to finish FY26 at 3.4–3.5x—modestly above the original guidance and driven by both lower-than-expected EBITDA (due to 2% volume declines vs. guidance assumptions) and the inventory impact—pushing the company further from its long-term target of 2.5–3x leverage. Although Amcor remains committed to deleveraging, the path back to target relies on uncertain assumptions about continued synergy capture and divestiture proceeds, both of which face execution risks. The company has made progress on noncore divestitures, closing six deals worth ~$500 million in transaction value, yet it admittedly remains in early stages on share gain efforts and has not demonstrated an ability to meaningfully offset volume declines through market share gains despite its global scale. Volume performance continues to lag, with overall volumes down 1.5% in Q3 FY26—equally split between core and noncore businesses—and only emerging markets showing mid-single-digit growth, while North America and Europe remain weak due to winter storm impacts and softer demand. Even the focus categories, while outperforming the total company, were merely flat, signaling a lack of underlying organic growth momentum. Furthermore, while management highlights collaborative pricing discussions with customers to pass through inflation, they conceded that 30% of the business lacks contracted pricing and relies on general price increases, leaving a meaningful portion exposed to margin pressure if consumer resistance limits their ability to pass along costs. The healthcare segment—a stated focus area—remained a particular point of weakness, with volumes slightly down despite positives like new facility openings and pharma wins, suggesting that even in preferred end markets, demand is fragile. Finally, the upcoming fiscal year-end change to December 31, while intended to improve comparability, introduces a six-month stub period (July–December 2026) that could complicate year-over-year comparisons and obscure trends during a potentially volatile macroeconomic period. These factors collectively suggest the market may be ignoring the durability of Amcor’s earnings recovery and the risk that current cost-mitigation tactics are merely delaying, not solving, structural challenges in demand and pricing power.

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Packaging & Containers

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	BALL	BALL Corp	88.75 Bn	94.92	6.49	7.14 Bn
2	IP	International Paper Co /New/	24.05 Bn	-33.72	0.99	9.09 Bn
3	AVY	Avery Dennison Corp	12.53 Bn	18.16	1.39	3.79 Bn
4	CCK	Crown Holdings, Inc.	12.47 Bn	-11.53	0.98	5.75 Bn
5	REYN	Reynolds Consumer Products Inc.	5.71 Bn	17.42	1.51	1.53 Bn
6	SON	Sonoco Products Co	5.57 Bn	16.33	0.74	4.69 Bn
7	SLGN	Silgan Holdings Inc	4.87 Bn	17.36	0.74	4.66 Bn
8	GPK	Graphic Packaging Holding Co	3.15 Bn	11.53	0.36	5.75 Bn

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password